Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Attenuated live cholera vaccine strain CVD 103-HgR elicits significantly higher serum vibriocidal antibody titers in persons of blood group O.

Literature DB >> 7822046

Attenuated live cholera vaccine strain CVD 103-HgR elicits significantly higher serum vibriocidal antibody titers in persons of blood group O.

R Lagos¹, A Avendaño, V Prado, I Horwitz, S Wasserman, G Losonsky, S Cryz, J B Kaper, M M Levine.

Abstract

Persons of blood group O are at increased risk of developing cholera gravis. In a randomized, placebo-controlled, double-blind safety-immunogenicity trial of live oral cholera vaccine CVD 103-HgR in 5- to 9-year-old Chilean children, vibriocidal antibody seroconversion (74% overall) did not differ by blood group. However, the reciprocal geometric mean titer (GMT) in blood group O vaccines (GMT = 486) was higher than that in non-O vaccines (GMT = 179) (P < 0.02).

Entities: Species

Mesh：

Substances：

Year: 1995 PMID： 7822046 PMCID： PMC173056 DOI： 10.1128/iai.63.2.707-709.1995

Source DB: PubMed Journal: Infect Immun ISSN： 0019-9567 Impact factor: 3.441

29 in total

1. Safety and immunogenicity in North Americans of a single dose of live oral cholera vaccine CVD 103-HgR: results of a randomized, placebo-controlled, double-blind crossover trial.

Authors: K L Kotloff; S S Wasserman; S O'Donnell; G A Losonsky; S J Cryz; M M Levine
Journal: Infect Immun Date: 1992-10 Impact factor: 3.441

Review 2. Live oral vaccines against cholera: an update.

Authors: M M Levine; J B Kaper
Journal: Vaccine Date: 1993 Impact factor: 3.641

3. [Tolerance and immunogenicity of an oral dose of CVD 103-HgR, a live attenuated Vibrio cholerae 01 strain: a double-blind study of Chilean adults].

Authors: R Lagos; A Avendaño; I Horwitz; V Prado; C Ferreccio; V Sotomayor; G Losonsky; S S Wasserman; S Cryz; J B Kaper
Journal: Rev Med Chil Date: 1993-08 Impact factor: 0.553

4. Safety, immunogenicity, and excretion pattern of single-dose live oral cholera vaccine CVD 103-HgR in Peruvian adults of high and low socioeconomic levels.

Authors: E Gotuzzo; B Butron; C Seas; M Penny; R Ruiz; G Losonsky; C F Lanata; S S Wasserman; E Salazar; J B Kaper
Journal: Infect Immun Date: 1993-09 Impact factor: 3.441

5. Duration of infection-derived immunity to cholera.

Authors: M M Levine; R E Black; M L Clements; L Cisneros; D R Nalin; C R Young
Journal: J Infect Dis Date: 1981-06 Impact factor: 5.226

6. Safety, immunogenicity, and transmissibility of single-dose live oral cholera vaccine strain CVD 103-HgR in 24- to 59-month-old Indonesian children.

Authors: C H Simanjuntak; P O'Hanley; N H Punjabi; F Noriega; G Pazzaglia; P Dykstra; B Kay; A Budiarso; A R Rifai
Journal: J Infect Dis Date: 1993-11 Impact factor: 5.226

7. Attachment of Helicobacter pylori to human gastric epithelium mediated by blood group antigens.

Authors: T Borén; P Falk; K A Roth; G Larson; S Normark
Journal: Science Date: 1993-12-17 Impact factor: 47.728

8. Genetic susceptibility to cholera.

Authors: M M Levine; D R Nalin; M B Rennels; R B Hornick; S Sotman; G Van Blerk; T P Hughes; S O'Donnell; D Barua
Journal: Ann Hum Biol Date: 1979 Jul-Aug Impact factor: 1.533

9. Characterization and distribution of the hemagglutinins produced by Vibrio cholerae.

Authors: L F Hanne; R A Finkelstein
Journal: Infect Immun Date: 1982-04 Impact factor: 3.441

10. [Assessment and standardization of the body mass index in French males aged 18-59 years].

Authors: J C Pineau; S Vol; J Tichet
Journal: C R Acad Sci III Date: 1995-06

21 in total

1. A large study on immunological response to a whole-cell killed oral cholera vaccine reveals that there are significant geographical differences in response and that O blood group individuals do not elicit a higher response.

Authors: T Ramamurthy; Diane Wagener; Goutam Chowdhury; Partha P Majumder
Journal: Clin Vaccine Immunol Date: 2010-06-16

2. Safety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-HgR, prepared from new master and working cell banks.

Authors: Wilbur H Chen; Richard N Greenberg; Marcela F Pasetti; Sofie Livio; Michael Lock; Marc Gurwith; Myron M Levine
Journal: Clin Vaccine Immunol Date: 2013-10-30

3. Evaluation of a bivalent (CVD 103-HgR/CVD 111) live oral cholera vaccine in adult volunteers from the United States and Peru.

Authors: D N Taylor; C O Tacket; G Losonsky; O Castro; J Gutierrez; R Meza; J P Nataro; J B Kaper; S S Wasserman; R Edelman; M M Levine; S J Cryz
Journal: Infect Immun Date: 1997-09 Impact factor: 3.441

Review 4. Factors That Influence the Immune Response to Vaccination.

Authors: Petra Zimmermann; Nigel Curtis
Journal: Clin Microbiol Rev Date: 2019-03-13 Impact factor: 26.132

Review 5. Maximizing protection from use of oral cholera vaccines in developing country settings: an immunological review of oral cholera vaccines.

Authors: Sachin N Desai; Alejandro Cravioto; Dipika Sur; Suman Kanungo
Journal: Hum Vaccin Immunother Date: 2014-05-26 Impact factor: 3.452

10. A single dose of live oral cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-infected and HIV-noninfected adults in Mali.

Authors: R T Perry; C V Plowe; B Koumaré; F Bougoudogo; K L Kotloff; G A Losonsky; S S Wasserman; M M Levine
Journal: Bull World Health Organ Date: 1998 Impact factor: 9.408